Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 331

Sort by

Sort Order Select

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

https://doi.org/10.1182/blood-2019-122350

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples

Jonathan Rink, PhD, Adam Yuh Lin, MD PhD, Shuo Yang, PhD, Amir Behdad, MD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 2857.

https://doi.org/10.1182/blood-2019-127805

Published: 2019

Journal Articles

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

Idaly Maria Olivas, BS, Joshua Lara, BS, Rebecca Ellwood, MS, Carme Ripoll Fiol, MS, Andres J Rubio, MS, Alfonso Enrique Bencomo, PhD, Mayra Alejandra Gonzalez, BS, Georgios Nteliopoulos, PhD, Alistair Reid, BSc, PhD, Dragana Milojkovic, MBBS, MD, Jane Apperley, MB, ChB, MD, Jamshid Sorouri Khorashad, MD PhD FRCPath, Anna M. Eiring, PhD

Blood (2019) 134 (Supplement_1): 2923.

https://doi.org/10.1182/blood-2019-126963

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Karen Dybkær, PhD, Hanne Due, MSc, Rasmus Froberg Brøndum, PhD, Ken H. Young, MD PhD, Martin Bøgsted, PhD

Blood (2019) 134 (Supplement_1): 1623.

https://doi.org/10.1182/blood-2019-122351

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Adam Yuh Lin, MD PhD, Jonathan Rink, PhD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 1577.

https://doi.org/10.1182/blood-2019-125308

Published: 2019

Journal Articles

Exploring PRMT5 As a Potential Therapeutic Target in Canine Lymphomas

Kyle Renaldo, DVM, MS, Shelby Sloan, BS, JiHyun Chung, PhD, Lindsay Courtney, BS, Konstantin Shilo, MD, William Kisseberth, DVM, PhD, Robert A Baiocchi, MD PhD

Blood (2018) 132 (Supplement 1): 4182.

https://doi.org/10.1182/blood-2018-99-119115

Published: 2018

Journal Articles

Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Marius Bill, MD PhD, Dario Veneziano, PhD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Giovanni Nigita, PhD, Maria G. Krantz, Deedra Nicolet, MS, Dimitrios Papaioannou, MD, Allison Walker, Zachary Brannan, Bayard L. Powell, MD, Richard M. Stone, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Eunice S. Wang, MD, Adrienne M. Dorrance, PhD, Carlo M. Croce, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2018) 132 (Supplement 1): 89.

https://doi.org/10.1182/blood-2018-99-115270

Published: 2018

Journal Articles

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

Karilyn Larkin, MD, Erin Guth, MS, Bonnie K. Harrington, DVM, Nicole Grieselhuber, MD PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 4056.

https://doi.org/10.1182/blood-2018-99-117262

Published: 2018

Journal Articles

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Aniket Bankar, MBBS, MD DM, Thirushi Piyumika Siriwardena, Biljana Rizoska, PhD, Christina Rydergård, BSc, Helen Kylefjord, BSc, Vilma Rraklli, PhD, Anders Eneroth, PhD, Pedro Pinho, PhD, Stefan Norin, MD PhD, Johan Bylund, PhD, Sara Moses, PhD, Richard Bethell, PhD, Simon Kavanagh, MBBS(Hons), FRACP, FRCPA, Xiaoming Wang, Rose Hurren, BSc, Mark D. Minden, MD PhD, Paul Targett-Adams, PhD BSc, Aaron D Schimmer, MD PhD, Mark Albertella, PhD

Blood (2018) 132 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2018-99-114345

Published: 2018

Journal Articles

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

Ying Wang, MD, Yingxi Xu, PhD, Qian Liu, Haiyan Xing, MS, Zheng Tian, BS, Kejing Tang, BS, Qing Rao, MS, Min Wang, MD, Jianxiang Wang, MD

Blood (2018) 132 (Supplement 1): 5130.

https://doi.org/10.1182/blood-2018-99-112728

Published: 2018

Journal Articles

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Mira A. Kohorst, MD, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Cristina Correia, Keith W. Pratz, MD, B. Douglas Smith, MD, Scott H. Kaufmann, MD PhD

Blood (2018) 132 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2018-99-115667

Published: 2018

Journal Articles

Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Thorsten Braun, MD PhD, Jeannig Berrou, Renaud Prudent, Hanane Djamai, Melanie Dupont, Anna Kaci, Emilie Adiceam, Fabrice Paublant, Andre Baruchel, MD, Jacques Ghysdael, Claude Gardin, Herve Dombret

Blood (2018) 132 (Supplement 1): 2705.

https://doi.org/10.1182/blood-2018-99-115933

Published: 2018

Journal Articles

Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia

Victoria Y Ling, MBBS, William Godfrey, Sebastien Jacquelin, PhD, Jasmin Straube, PhD, Leanne T Cooper, Claudia Bruedigam, PhD, Siok-Keen Tey, MBBS PhDFRACP FRCPA, Lars Bullinger, MD, Marco J Herold, Megan Bywater, PhD, Steven W. Lane, MD PhD

Blood (2018) 132 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2018-99-115729

Published: 2018

Journal Articles

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Samir H Barghout, BSPharm, MSc, Neil MacLean, G. Wei Xu, Geethu Thomas, PhDMSc,BSc, Zachary Blatman, Rose Hurren, BSc, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2018-99-110406

Published: 2018

Journal Articles

The Novel Small Molecule Inhibitor KS99 Targets AML and Inhibits Stemness Markers STAT3 and ALDH

Charyguly Annageldiyev, Krishne Gowda, Dhimant Desai, Viola Devine, Daniel Brosius, Chandrika Gowda, MBBS, Sinisa Dovat, MD PhD, Shantu Amin, David F. Claxton, MD, Arati Sharma, PhD

Blood (2018) 132 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2018-99-117376

Published: 2018

Journal Articles

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Paola Minetto, MD, Debora Soncini, PhD, Fabio Guolo, MD, Samantha Ruberti, BSc, PhD, Veronica Retali, Paola Contini, Nadia Bisso, MD, Nikki Di Felice, MD, Giulia Rivoli, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD, Michele Cea, MD

Blood (2018) 132 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2018-99-119622

Published: 2018

NARROW

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Exploring PRMT5 As a Potential Therapeutic Target in Canine Lymphomas

Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

The Novel Small Molecule Inhibitor KS99 Targets AML and Inhibits Stemness Markers STAT3 and ALDH

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only